Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Re.: Oral administration of a certain strain of live Escherichia coli for intestinal disorders? (Infection 23 [1995] 51-54)

× No keyword cloud information.

10 in total

1. The antibody response in infants after colonization of the intestine with E. coli O83. Artificial colonization used as a prevention against nosocomial infections.

Authors: R Lodinová-Zádníková; H Tlaskalová; Z Bartáková
Journal: Adv Exp Med Biol Date: 1991 Impact factor: 2.622

2. [Experimenta colonization of the intestinal tract in newborns with Escherichia coli type 083 and studies on the formation of antibodies].

Authors: R Lodinová; V Jouja; A Lanc
Journal: Z Immunitatsforsch Allerg Klin Immunol Date: 1967-08

3. Implantation and in vivo antagonistic effects of antibiotic-susceptible Escherichia coli strains administered to premature newborns.

Authors: A Rastegar Lari; F Gold; J C Borderon; J Laugier; J P Lafont
Journal: Biol Neonate Date: 1990

4. Oral administration of a certain strain of live Escherichia coli for intestinal disorders? Artificial contamination and manipulation of the digestive tract--our poor GIT!

Authors:
Journal: Infection Date: 1995 Jan-Feb Impact factor: 3.553

5. [Implantation of a strain of "Escherichia coli" in the digestive tract of human new-borns: barrier effect against antibioresistant "E. coli" (author's transl)].

Authors: Y Duval-Iflah; M F Ouriet; C Moreau; N Daniel; J C Gabilan; P Raibaud
Journal: Ann Microbiol (Paris) Date: 1982 May-Jun

6. [Immunomodulating effect of killed, apathogenic Escherichia coli, strain Nissle 1917, on the macrophage system].

Authors: S Hockertz
Journal: Arzneimittelforschung Date: 1991-10

7. Evolution of the barrier effects against an exogenous drug-sensitive Escherichia coli strain after single or repeated oral administration to newborns and infants aged up to three months admitted to an intensive-care unit.

Authors: D M Poisson; J C Borderon; J C Amorim-Sena; J Laugier
Journal: Biol Neonate Date: 1986

8. The antibody response in breast-fed and non-breast-fed infants after artificial colonization of the intestine with Escherichia coli O83.

Authors: R Lodinová-Zádníková; M Slavíková; H Tlaskalová-Hogenová; I Adlerberth; L A Hanson; A Wold; B Carlsson; C Svanborg; L Mellander
Journal: Pediatr Res Date: 1991-04 Impact factor: 3.756

9. [Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor)].

Authors: M Möllenbrink; E Bruckschen
Journal: Med Klin (Munich) Date: 1994-11-15

10. Influence of the intestinal flora on the development of immune reactions in infants.

Authors: R Lodinova; V Jouja; A Lanc
Journal: J Bacteriol Date: 1967-03 Impact factor: 3.490

10 in total

15 in total

1. Type 1 fimbriation and phase switching in a natural Escherichia coli fimB null strain, Nissle 1917.

Authors: B Stentebjerg-Olesen; T Chakraborty; P Klemm
Journal: J Bacteriol Date: 1999-12 Impact factor: 3.490

2. Functional genomics of probiotic Escherichia coli Nissle 1917 and 83972, and UPEC strain CFT073: comparison of transcriptomes, growth and biofilm formation.

Authors: Viktoria Hancock; Rebecca Munk Vejborg; Per Klemm
Journal: Mol Genet Genomics Date: 2010-10-01 Impact factor: 3.291

3. Promising discovery of beneficial Escherichia coli in the human gut.

Authors: Atchareeya Nakkarach; Hooi Ling Foo; Adelene Ai-Lian Song; Sunee Nitisinprasert; Ulaiwan Withayagiat
Journal: 3 Biotech Date: 2020-06-09 Impact factor: 2.406

Review 4. Biodiversity of Intestinal Lactic Acid Bacteria in the Healthy Population.

Authors: Marika Mikelsaar; Epp Sepp; Jelena Štšepetova; Epp Songisepp; Reet Mändar
Journal: Adv Exp Med Biol Date: 2016 Impact factor: 2.622

Review 5. Diet therapy for inflammatory bowel diseases: The established and the new.

Authors: Franziska Durchschein; Wolfgang Petritsch; Heinz F Hammer
Journal: World J Gastroenterol Date: 2016-02-21 Impact factor: 5.742

6. Enhanced wound healing by recombinant Escherichia coli Nissle 1917 via human epidermal growth factor receptor in human intestinal epithelial cells: therapeutic implication using recombinant probiotics.

Authors: Hye Jin Choi; Jung Hoon Ahn; Seong-Hwan Park; Kee Hun Do; Juil Kim; Yuseok Moon
Journal: Infect Immun Date: 2011-12-19 Impact factor: 3.441

7. Escherichia coli EDL933 requires gluconeogenic nutrients to successfully colonize the intestines of streptomycin-treated mice precolonized with E. coli Nissle 1917.

Authors: Silvia A C Schinner; Matthew E Mokszycki; Jimmy Adediran; Mary Leatham-Jensen; Tyrrell Conway; Paul S Cohen
Journal: Infect Immun Date: 2015-03-02 Impact factor: 3.441

8. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.

Authors: W Kruis; P Fric; J Pokrotnieks; M Lukás; B Fixa; M Kascák; M A Kamm; J Weismueller; C Beglinger; M Stolte; C Wolff; J Schulze
Journal: Gut Date: 2004-11 Impact factor: 23.059

9. An Escherichia coli Nissle 1917 missense mutant colonizes the streptomycin-treated mouse intestine better than the wild type but is not a better probiotic.

Authors: Jimmy Adediran; Mary P Leatham-Jensen; Matthew E Mokszycki; Jakob Frimodt-Møller; Karen A Krogfelt; Krystyna Kazmierczak; Linda J Kenney; Tyrrell Conway; Paul S Cohen
Journal: Infect Immun Date: 2013-11-25 Impact factor: 3.441

10. A Simple In Vitro Gut Model for Studying the Interaction between Escherichia coli and the Intestinal Commensal Microbiota in Cecal Mucus.

Authors: Matthew E Mokszycki; Mary Leatham-Jensen; Jon L Steffensen; Ying Zhang; Karen A Krogfelt; Matthew E Caldwell; Tyrrell Conway; Paul S Cohen
Journal: Appl Environ Microbiol Date: 2018-11-30 Impact factor: 4.792